JPMorgan raised the firm’s price target on Alnylam (ALNY) to $338 from $330 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect higher Amvuttra estimates.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Cautious Outlook on Alnylam Pharma: Hold Rating Amid Incremental EU Approval and Promising US Sales Projections
- Alnylam receives European Commission approval of AMVUTTRA
- Alnylam Pharma’s Strong Execution and Innovation in ATTR-CM Space Drives Positive Outlook
- Promising Market Outlook and Strong Product Pipeline Drive Buy Rating for Alnylam Pharma
- Positive Buy Rating for Alnylam Pharma Driven by Promising Clinical Data and Strategic Advancements
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue